Profitability Improvement
TECH achieved a 95% increase in operating income and a 126% rise in net income, primarily due to a 27.7% reduction in SG&A expenses.
Source: 10-Q Income Statement
Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
TECH's Q3 FY2026 results show a significant improvement in profitability despite a slight decline in revenue, driven by cost reductions and increased operational efficiency.
Revenue
$311.42M
-1.51% YoY
EPS (Diluted)
$0.32
+128.57% YoY
Gross Margin
66.9%
-1.0 pts YoY
Operating Income
$75.5M
+95.04% YoY
Source: SEC XBRL
BIO-TECHNE (TECH) reported Q3 FY2026 revenue of $311.42M, down 1.5% year over year. Operating margin was 24.2%, up 12.0 points from 12.2% a year earlier. TECH's fiscal Q3 FY2026 corresponds to calendar Q1 2026.
Last 4 quarters: 1 beat
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Jun 2026 | 0.52 | 0.53 | Miss -1.8% |
| Mar 2026This filing | 0.53 | 0.55 | Miss -3.3% |
| Dec 2025 | 0.46 | 0.44 | Beat +4.0% |
| Sep 2025 | 0.42 | 0.43 | Miss -2.0% |
Adjusted (non-GAAP) EPS of $0.53 versus the $0.55 analyst consensus — a -3.3% miss for Mar 2026. Analyst consensus is quoted on the adjusted (non-GAAP) basis the street uses. GAAP diluted EPS for this quarter was $0.32.
Compiled by AI from this SEC filing
TECH achieved a 95% increase in operating income and a 126% rise in net income, primarily due to a 27.7% reduction in SG&A expenses.
Source: 10-Q Income Statement
Revenue decreased by 1.5% year-over-year, indicating challenges in maintaining sales growth.
Source: 10-Q Income Statement
Cash and equivalents increased by 49.2%, enhancing liquidity and financial flexibility.
Source: 10-Q Balance Sheet
Compiled by AI from this SEC filing · 0 high, 2 medium, 1 low
The 1.5% year-over-year decline in revenue suggests potential challenges in market demand or competitive pressures.
Source: 10-Q Income Statement
While SG&A expenses were reduced significantly, maintaining this cost discipline is crucial for future profitability.
Source: 10-Q Income Statement
A 3.5% decrease in total assets could impact long-term growth if not managed carefully.
Source: 10-Q Balance Sheet
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $M | 311.42 $M | 316.18 $M | -1.51% |
Cost of Revenue $M | 103.13 $M | 101.63 $M | +1.48% |
Gross Profit $M | 208.29 $M | 214.56 $M | -2.92% |
Operating Income $M | 75.50 $M | 38.71 $M | +95.04% |
Net Income $M | 51.05 $M | 22.59 $M | +125.99% |
EPS (Basic) $ | 0.33 $ | 0.14 $ | +135.71% |
EPS (Diluted) $ | 0.32 $ | 0.14 $ | +128.57% |
SG&A Expense $M | 109.34 $M | 151.27 $M | -27.72% |
Answers draw on this SEC filing and the data on this page
Bio-Techne agreed to be acquired by Merck KGaA for $73.00 per share in cash while FY2026 results showed flat revenue, a reported earnings surge from prior-year charges, and a 1% decline in adjusted net earnings.
TECH's Q2 FY2026 results show a slight decline in revenue but improved operating income and net income, highlighting effective cost management despite revenue pressures.
Other companies in Life Sciences Tools & Services